---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011878"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:02:27.747550+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises

## Summary
- Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
- Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.
- Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.
- Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications.

## SEC filing metadata
- accession: 0001641172-25-011878
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/0001641172-25-011878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011878
- JSON: https://secwatch.observer/filing/0001641172-25-011878.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.